한글목차

세계의 디지털 바이오마커 시장은 2025년 51억 5,000만 달러로 추정되며, 2032년까지 401억 6,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지 연평균 성장률(CAGR) 34.1%로 성장할 전망입니다.

디지털 바이오마커란 휴대용 기기, 웨어러블 기기, 임플란트 기기, 소화기관 등의 디지털 기기를 통해 수집· 및 정되는 객관적이고 정량화 가능한 생리학적 및 행동학적 데이터로 정의됩니다.

시장 역학:

만성질환 시장개척, 디지털 헬스케어 솔루션의 채용 확대, 연구개발 증가, 환자 중심의 헬스케어 용도의 채용 확대, 스마트폰의 사용 증가, 참신한 웨어러블의 출현, 치료 용도의 확대 등이 디지털 바이오마커 세계 시장 성장을 가속할 것으로 예상되는 주요 요인입니다.

예를 들어, 2023년 2월, Ad Scientiam사는 중증근무력증(gMG)과 시신경 척수염 스펙트럼 장애(NMOSD)를 앓고 있는 환자의 자기 평가를 위한 디지털 바이오마커를 개발 및 검증하는 2개의 의욕적인 프로그램의 개시를 발표했습니다. 이 프로그램은 Ad Scientiam사가 지난 5년간 구축한 자산, 수법, 전문지식을 활용하는 것으로, Alexion, AstraZeneca Rare Disease의 지원을 받고 있습니다.

본 조사의 주요 특징

• 본 보고서는 세계의 디지털 바이오마커 시장을 상세하게 분석하여 2024년을 기준연도로 하여 2025-2032년의 예측기간 중 시장 규모 및 복합연간 성장률(CAGR%)을 제공합니다.
• 또한 다양한 부문에서 잠재적인 수익 기회를 밝혀 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 발매 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 주요 고찰도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 아래의 파라미터를 바탕으로 세계 디지털 바이오마커 시장의 주요 기업 프로파일을 제공합니다.
• 본 보고서로부터의 통찰에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 발매, 유형, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 디지털 바이오마커 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 하고 있습니다.
• 이해관계자는 세계 디지털 바이오마커 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 디지털 헬스케어 솔루션 도입 확대
  • 고액의 자본 투자와 데이터 보안에 대한 우려
  • 건강 관련 모바일 애플리케이션의 급속한 보급
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 출시/승인
• PEST 분석
• PORTER 분석
• 합병과 인수 시나리오

제4장 세계 디지털 바이오마커 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 디지털 바이오마커 시장 : 데이터 수집 툴별, 2020-2032년

• 웨어러블 디바이스
• 내장형 부품 및 센서
• 모바일 및 태블릿 앱
• 플랫폼
• 데스크톱 기반 소프트웨어
• 데이터 통합(데이터 통합 시스템)

제6장 세계의 디지털 바이오마커 시장 : 용도별, 2020-2032년

• 수면과 운동
• 심혈관 질환
• 기분 및 행동
• 통증 관리
• 신경퇴행성 질환
• 호흡기 질환

제7장 세계 디지털 바이오마커 시장 : 최종 사용자별, 2020-2032년

• 바이오의약품기업
• 제공업체
• 지불자

제8장 세계의 디지털 바이오마커 시장 : 지역별, 2020-2032년

• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제9장 경쟁 구도

• AliveCor Inc.
• Altoida Inc.
• Amgen Inc.
• Human API
• Fitbit, Inc.
• Biogen Inc.
• Bayer AG
• Akili Interactive Labs
• Evidation Health, Inc.
• GlaxoSmithKline Plc
• Eli Lilly and Company

제10장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Digital Biomarkers Market is estimated to be valued at USD 5.15 Bn in 2025 and is expected to reach USD 40.16 Bn by 2032, growing at a compound annual growth rate (CAGR) of 34.1% from 2025 to 2032.

Digital biomarkers are defined as objective, quantifiable physiological & behavioral data collected and measured through digital devices such as portables, wearables, implantables, and/or digestible. The data collected by these digital devices is typically used to explain, influence, or predict health-related outcomes. Thus, the demand for digital biomarkers is increasing with a rapid pace.

Market Dynamics:

Growing prevalence of chronic diseases, rising adoption of digital healthcare solutions, increasing research and development, growing adoption of patient-centric healthcare applications, rising use of smartphones, emergence of novel wearables, and expanding therapeutic applications are major factors expected to drive growth of the global digital biomarkers market.

For instance, in February 2023, Ad Scientiam announced the launch of two ambitious programs to develop and validate digital biomarkers for self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies, and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.

Key features of the study:

• This report provides in-depth analysis of the global digital biomarkers market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global digital biomarkers market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include AliveCor Inc., Altoida Inc., Amgen Inc., Human API, Fitbit, Inc., Biogen Inc, Bayer AG, Akili Interactive Labs, Evidation Health, Inc., GlaxoSmithKline Plc, and Eli Lilly and Company, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global digital biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global digital biomarkers market.

Detailed Segmentation:

• Global Digital Biomarkers Market, By Data Collection Tools:
  • Wearable Devices
  • Implantable Components/Sensors
  • Mobile/Tablet Apps
  • Platforms
  • Desktop Based Software
  • Data Integration (Systems that Integrate Data)
• Global Digital Biomarkers Market, By Application:
  • Sleep and Movement
  • Cardiovascular Disease
  • Mood and Behavior
  • Pain Management
  • Neurodegenerative Disorders
  • Respiratory Conditions
• Global Digital Biomarkers Market, By End User:
  • Biopharmaceutical Companies
  • Providers
  • Payers
• Global Digital Biomarkers Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • AliveCor Inc.
  • Altoida Inc.
  • Amgen Inc.
  • Human API
  • Fitbit, Inc.
  • Biogen Inc.
  • Bayer AG
  • Akili Interactive Labs
  • Evidation Health, Inc.
  • GlaxoSmithKline Plc
  • Eli Lilly and Company

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Digital Biomarkers, By Data Collection Tools
  • Market Digital Biomarkers, By Application
  • Market Digital Biomarkers, By End User
  • Market Digital Biomarkers, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing adoption of digital healthcare solutions
  • High capital investment and data security concerns
  • Rapid adoption of health-related mobile applications
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Digital Biomarkers Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Digital Biomarkers Market, By Data Collection Tools, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Wearable Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Implantable Components/Sensors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Mobile/Tablet Apps
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Platforms
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Desktop Based Software
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Data Integration (Systems that Integrate Data)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Digital Biomarkers Market, By Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Sleep and Movement
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Cardiovascular Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Mood and Behavior
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Pain Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Neurodegenerative Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Respiratory Conditions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Digital Biomarkers Market, By End User, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Biopharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Providers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Payers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Digital Biomarkers Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Data Collection Tools, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Data Collection Tools, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Data Collection Tools, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Data Collection Tools, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Data Collection Tools, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Data Collection Tools, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)

9. Competitive Landscape

• AliveCor Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Altoida Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Human API
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fitbit, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biogen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Akili Interactive Labs
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Evidation Health, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline Plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us